3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
70
Neoplasms
47
Carcinoma, Non-Small-Cell Lung
26
Colorectal Neoplasms
20
Neoplasm Metastasis
15
Multiple Myeloma
14
Thyroid Neoplasms
12
Glioma
12
Pancreatic Neoplasms
11
Hematologic Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Brain Neoplasms
8
Lung Neoplasms
7
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Neurofibromatosis 1
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Colonic Neoplasms
5
Breast Neoplasms
5
Astrocytoma
5
Thyroid Cancer, Papillary
4
Prostatic Neoplasms
4
Neurofibroma, Plexiform
4
Glioblastoma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uveal Melanoma
3
Skin Neoplasms
3
Recurrence
3
Interventions
Cisplatin
35
Radiotherapy
20
Magnetic Resonance Spectroscopy
19
Cetuximab
17
Specimen Handling
15
pembrolizumab
13
Carboplatin
13
Radiotherapy, Intensity-Modulated
12
Fluorouracil
12
Docetaxel
12
1,2-diaminocyclohexaneplatinum II citrate
10
Radiation
9
Platinum
9
Paclitaxel
8
Surgical Procedures, Operative
7
Drug Therapy
6
Biopsy
6
Taxes
5
toripalimab
4
X-Rays
4
Standard of Care
4
Fluorodeoxyglucose F18
4
Celecoxib
4
(225)Ac-DOTA-c(RGDyK)
4
cemiplimab
3
Nutritional Status
3
Laser Therapy
3
Interviews as Topic
3
Hydroxyurea
3
130-nm albumin-bound paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Laryngeal Neoplasms
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled